iShares U.S. Medical Devices ETF
IHIDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 19, 2025 | $0.06 | 2025-12-16 | 2025-12-16 |
| September 19, 2025 | $0.06 | 2025-09-16 | 2025-09-16 |
| June 20, 2025 | $0.06 | 2025-06-16 | 2025-06-16 |
| March 21, 2025 | $0.03 | 2025-03-18 | 2025-03-18 |
| December 20, 2024 | $0.11 | 2024-12-17 | 2024-12-17 |
Dividends Summary
- Consistent Payer: iShares U.S. Medical Devices ETF has rewarded shareholders with 65 dividend payments over the past 17 years.
- Total Returned Value: Investors who held IHI shares during this period received a total of $8.38 per share in dividend income.
- Latest Payout: The most recent dividend of $0.06/share was paid 35 days ago, on December 19, 2025.
- Yield & Schedule: IHI currently pays dividends quarterly with an annual yield of 0.35%.
- Dividend Growth: Since 2008, the dividend payout has grown by 59.7%, from $0.04 to $0.06.
Company News
Becton, Dickinson and Company received FDA 510(k) clearance for its EnCor EnCompass Breast Biopsy and Tissue Removal System, with market launch expected in early 2026. The advanced system features high and low vacuum strengths, 360-degree sampling ability, and multiple probe options. However, analysts expect slightly lower earnings and revenue co...
Boston Scientific agreed to acquire thrombectomy specialist Penumbra for $14.5 billion ($374 per share) in a cash-and-stock deal. Penumbra shareholders will receive approximately 73% cash and 27% equity. The acquisition allows Boston Scientific to enter fast-growing vascular segments. Penumbra reported strong preliminary Q4 2025 results with 21-2...
Samsung Electronics plans to acquire Xealth, a digital health platform, to integrate wearable device data with hospital systems, enhancing personalized healthcare and advancing its digital health strategy.
The healthcare sector has faced several headwinds in 2025, leading to lower earnings growth expectations. However, the sector is still expected to be one of the strongest performers in the S&P 500 this year, and some individual stocks and ETFs have shown resilience.
President Trump signed an executive order aimed at reducing prescription drug prices in the U.S. by tying them to the lowest prices paid in other countries. However, legal experts have raised concerns about the legality of the order, and it may face similar challenges as a previous attempt in 2020.
